301 related articles for article (PubMed ID: 18465341)
41. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
42. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
[TBL] [Abstract][Full Text] [Related]
43. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M
J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390
[TBL] [Abstract][Full Text] [Related]
44. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I
Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371
[TBL] [Abstract][Full Text] [Related]
45. DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients.
Ejlertsen B; Jensen MB; Mouridsen HT; Andersen J; Cold S; Jakobsen E; Kamby C; Sørensen PG; Ewertz M
Acta Oncol; 2008; 47(4):709-17. PubMed ID: 18465339
[TBL] [Abstract][Full Text] [Related]
46. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
47. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
48. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
49. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
[TBL] [Abstract][Full Text] [Related]
50. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
51. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.
Nielsen KV; Ejlertsen B; Møller S; Jensen MB; Balslev E; Müller S; Knoop A; Mouridsen HT
Mol Oncol; 2012 Feb; 6(1):88-97. PubMed ID: 22153616
[TBL] [Abstract][Full Text] [Related]
52. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
53. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Jaremko M; Justenhoven C; Schroth W; Abraham BK; Fritz P; Vollmert C; Illig T; Simon W; Schwab M; Brauch H
Pharmacogenet Genomics; 2007 Jul; 17(7):529-38. PubMed ID: 17558308
[TBL] [Abstract][Full Text] [Related]
54. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
55. Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples.
Zaczek A; Markiewicz A; Jaśkiewicz J; Pieńkowski T; Rhone P; Jassem J; Wełnicka-Jaśkiewicz M
Clin Biochem; 2010 Jul; 43(10-11):891-8. PubMed ID: 20441774
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
57. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
58. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
Gennari A; Pronzato P
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039
[TBL] [Abstract][Full Text] [Related]
59. p53 as a specific prognostic factor in triple-negative breast cancer.
Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
Ejlertsen B; Tuxen MK; Jakobsen EH; Jensen MB; Knoop AS; Højris I; Ewertz M; Balslev E; Danø H; Vestlev PM; Kenholm J; Nielsen DL; Bechmann T; Andersson M; Cold S; Nielsen HM; Maae E; Carlsen D; Mouridsen HT
J Clin Oncol; 2017 Aug; 35(23):2639-2646. PubMed ID: 28661759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]